MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of

Industry Veteran Will Lead Company’s Commercial Growth Strategy in Americas Region MENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate, sequencing platforms, welcomes Lara Toerien, Ph.D., as Vice President and General

New collaboration builds on existing relationship between the two companies to develop desktop systems for the clinical market in China Berry Genomics to purchase at least 50 instruments at product launch MENLO PARK, Calif. and BEIJING, Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a

Pilot project designed to demonstrate the power of HiFi sequencing to effectively and efficiently identify novel variants following short-read genome sequencing MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate

Initial proof-of-concept work suggests strong potential to further improve PacBio’s highly accurate HiFi Sequencing with Google deep learning technologies MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing

MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021.

Added whole genome sequencing capacity enables the SOLVE-RD research program to significantly increase sample throughput MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud

PacBio’s Sequel IIe devices will support genomic researchers around the world MENLO PARK, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) today announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ.

The study will evaluate the impact of high-resolution genomes generated on PacBio technology in studying unsolved rare disease cases MENLO PARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- PacBio, a leading provider of high-quality, long-read sequencing platforms, and the  Care4Rare Canada Consortium

MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PacBio announced today that its executives will be speaking virtually at the following investor conference: 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 pm Eastern Time (9:00 am Pacific Time) The live webcast can